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at lower cost compared with gabapentin as monotherapy. Resulting in greater
satisfaction and better adherence to treatment.
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OBJECTIVES: Panitumumab, a fully human monoclonal antibody directed against
epidermal growth factor receptor (EGFR), is indicated as a monotherapy for the
treatment of patients with EGFR-expressing CRCm and non-mutated KRAS status.
The aim of this study was to conduct an economic evaluation of panitumumab vs
cetuximab in Mexican patients with CRCm. METHODS: A cost minimization anal-
ysis (CMA) was performed from a Public Healthcare System perspective consider-
ing a 20-week timeframe. The analysis compared the treatment costs of CRCm
patients with panitumumab and cetuximab. Only direct medical costs were con-
sidered. Drug cost for cetuximab was calculated according to Mexican Public
Healthcare Sector acquisition price list for 2010. Panitumumab price for the Mexi-
can Public Healthcare Sector was provided by Amgen Mexico ($94.36 MXP/mg).
Recommended doses and frequency were based on each product label and the
number of cycles was based on data from clinical trials. Anthropometric values
were obtained from published data in Mexican Public Healthcare Sector oncology
(CRCm) patients. The cost of administration was calculated from an official Mexi-
can Public Healthcare Sector price list for 2010. A probabilistic sensitivity analysis
was performed considering two scenarios: per vial of drug (assuming wastage of
unused medication) and per mg of drug (assuming no wastage). RESULTS: Panitu-
mumab resulted in an overall monthly cost savings of 20% (per vial scenario) and
12.4% (per mg sceanrio) compared with cetuximab. When the analysis was re-
stricted to the acquisition drug costs, monthly savings of panitumumab compared
with cetuximab were estimated to be 19.1% and 11.2% in per vial and per mg
scenarios, respectively. Regarding the sensitivity analysis, 100% of iterations re-
sulted cost-saving in both scenarios (per vials and per mg).CONCLUSIONS:Accord-
ing to these results, panitumumab represents a cost-saving strategy vs cetuximab
for the treatment of patients with CRCm in the Mexican setting.
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OBJECTIVOS: Realizar una evaluación económica del uso de Iopromide mediante
un sistema de aplicación en cascada (SIAC), frente a los demás medios de contraste
para radiología invasiva disponibles en Colombia e incluidos dentro del plan de
beneficios colombiano (POS). METODOLOGÍAS: Se realizó un análisis de minimi-
zación de costos comparando SIAC frente al uso de otros medios de contraste
convencionales en radiología invasiva desde la perspectiva del hospital. La efec-
tividad y seguridad del uso de Iopromide es similar a la de los ya incluidos en el POS
según reportes de estudios clínicos. Los costos y frecuencias de uso fueron obteni-
dos de tres hospitales en Colombia durante el primer trimestre del 2011. Se toma-
ron los costos promedios obtenidos de las diferentes observaciones. No se incluy-
eron costos por eventos adversos, por cuanto son similares en las diferentes
opciones. RESULTADOS: El costo de utilizar SIAC en un paciente promedio de 70 Kg
fue de USD 35.57 frente a USD 39.44 cuando se utilizó otros medios de contraste
convencional. Lo que representa un ahorro de USD 3.90 por paciente. La diferencia
fundamental se debió a menor desperdicio de medio de contraste y menor tiempo
requerido. El análisis de sensibilidad no muestra cambios en los resultados. El
análisis de impacto presupuestario muestra el importante ahorro que significaría
para el país la conversión tecnológica pasando de utilizar los medios actuales a la
nueva tecnología que utiliza el sistema de aplicación SIAC para un peso promedio
de adultos en Colombia de 70 kg. CONCLUSIONES: El uso de Iopromide mediante la
aplicación de SIAC sería mejor que utilizar otros medios de contraste por cuanto es
menos costoso y utilizado de manera adecuada tendrían igual efectividad a los
otros medios de contraste comparados y de esta manera incentiva la productividad
al interior de las unidades de radiología.
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OBJECTIVES: Cerebral aneurysms are pathological dilatations of the cerebrovascu-
lature that are prone to rupture. Risk of aneurysm rupture is determined by size,
location and patient co-morbidies, and five-year cumulative rupture rates have
been reported to be as high as 50% in giant aneurysms [1]. The current study was
undertaken to assess the differences in overall hospital discharge costs, length of
stay (LOS) and all-cause mortality rates between inpatients with ruptured versus.
unruptured cerebral aneurysms.METHODS:All inpatient discharges were selected
from the Premier Perspective™ Database that had a primary diagnosis code for a
ruptured or unruptured aneurysm, AND a primary procedure code for treatment of
the aneurysm between 1/1/2008 and 6/30/2010 (index hospitalization). Costs, LOS
and mortality were compared between ruptured and unruptured aneurysm
groups. To minimize differences in baseline characteristics between groups, pro-
pensity adjustment was performed for age, gender and severity of illness (based on
the Patient Refined Diagnosis Related Groups). RESULTS: A total of 2977 ruptured
and 3836 unruptured aneurysm discharges met the inclusion criteria for the study.
After 1:1 propensity matching, 1163 patients in each group were included in the
analysis for outcome comparisons. Mean total cost per discharge was significantly
higher in the ruptured group ($51,118, s.d. $33,790) than the unruptured group
($33,585, s.d. $32,255). Mean LOS was also significantly higher in the ruptured group
(13.6 days, s.d. 12.7) versus. the unruptured group (6.5 days, s.d. 11.2). The all-cause
mortality rate was significantly higher in ruptured (7.7%) versus. unruptured (1.8%)
cerebral aneurysms. CONCLUSIONS: Preventing rupture in patients with cerebral
aneurysms would likely decrease burden to the health care system, and also im-
prove survival rates for patients. 1International Study of Unruptured Intracranial
Aneurysms Investigators. Unruptured Intracranial Aneurysms: Natural History,
Clinical Outcome, and Risks of Surgical and Endovascular Treatment. ([1] Lancet;
2003; 362:103-10)
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OBJECTIVES: To estimate the costs of acute coronary syndrome in Mexico and its
impact on the Mexican healthcare system, considering direct and indirect cost
under the public and private perspectives to support further HTA incorporation.
METHODS: In this study we adopted the societal perspective, including the public
and private perspectives. Direct costs were retrieved from national databases and
only hospitalization period was considered. For indirect costs the Human Capital
Approach method was used with two major costs included in the analysis: loss of
productivity among patients that died of a MI or unstable angina event and the loss
of productivity of the period between the main event (MI or angina) and the return
to work (recovery time). For the study we assumed the age from 25 to 64 years old
as active labor age (65 is the age of retirement in Mexico), a recovery time of 3.4
months and the average income of the population to estimate the loss of produc-
tivity for each working month lost. RESULTS: The estimated direct costs associated
to Acute Coronary Syndrome for 2011 under the public perspective is
US$153,629,253 and for private it is US$179,725,285. The estimated indirect cost for
2011 is US$918,239,181. So, the total estimated costs for ACS in Mexico for 2011 is
US$1,251,593,719. CONCLUSIONS: Due the high impact of ACS costs for the Mexi-
can healthcare system (U$1,251,593,719), projected for the year of 2011, it is very
relevant to evaluate measures that can reduce such events beyond those already in
use.
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OBJECTIVES: To estimate the costs of acute coronary syndrome in Brazil and its
impact on the Brazilian healthcare system, considering direct and indirect cost
under the public and private perspectives to support further HTA incorporation.
METHODS: In this study we adopted the societal perspective, including the public
(SUS) and supplementary (SHS) healthcare system perspectives. Direct costs were
retrieved from national databases [1] and only hospitalization period was consid-
ered. For indirect costs the Human Capital Approach method was used with two
major costs included in the analysis: loss of productivity among patients that died
of a MI or unstable angina event and the loss of productivity of the period between
the main event (MI or angina) and the return to work (recovery time). For the study
we assumed the age from 25 to 64 years old as active labor age (65 is the age of
retirement in Brazil), a recovery time of 3.4 months and the average income of the
population to estimate the loss of productivity for each working month lost.
RESULTS: The estimated direct costs associated to Acute Coronary Syndrome for
2011 under the SUS perspective is US$ 314,080,370 and for SHS it is US$ 309,781,809.
The estimated indirect cost for 2011 is US$ 1,703,908,984. So, the total estimated
costs for ACS in Brazil for 2011 is US$ 2,327,771,163. CONCLUSIONS: Due the high
impact of ACS costs for the Brazilian healthcare system (U$ 2,327,771,163.11), pro-
jected for the year of 2011, it is very relevant to evaluate measures that can reduce
such events beyond those already in use.
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OBJECTIVOS: Estimar la razón costo-efectividad (RCE) del uso de los stents libera-
dores de fármaco (DES, drug eluting stent) comparado contra los stents desnudos
(BMS, bare metal stent) en una cohorte de pacientes con enfermedad coronaria en
el Instituto Mexicano del Seguro Social (IMSS). METODOLOGÍAS: Análisis de costo-
efectividad en una cohorte de pacientes isquémicos con indicación de ICP (Inter-
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